Your browser doesn't support javascript.
loading
Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar, Muhammad Imran; Roobol, Monique J; Ribal, Maria J; Abbott, Thomas; Agapow, Paul-Michael; Araujo, Sonia; Asiimwe, Alex; Auffray, Charles; Balaur, Irina; Beyer, Katharina; Bernini, Chiara; Bjartell, Anders; Briganti, Alberto; Butler-Ransohoff, John-Edward; Campi, Riccardo; Cavelaars, Marinel; De Meulder, Bertrand; Devecseri, Zsuzsanna; Voss, Marc Dietrich; Dimitropoulos, Konstantinos; Evans-Axelsson, Susan; Franks, Billy; Fullwood, Louise; Horgan, Denis; Smith, Emma Jane; Kiran, Amit; Kivinummi, Kati; Lambrecht, Mark; Lancet, Doron; Lindgren, Peter; MacLennan, Sara; MacLennan, Steven; Nogueira, Maria Manuela; Moen, Fredrik; Moinat, Maxim; Papineni, Kishore; Reich, Christian; Reiche, Kristin; Rogiers, Stijn; Sartini, Claudio; van Bochove, Kees; van Diggelen, Femke; Van Hemelrijck, Mieke; Van Poppel, Hein; Zong, Jihong; N'Dow, James.
Afiliação
  • Omar MI; Academic Urology Unit, University of Aberdeen, Aberdeen, UK. m.i.omar@abdn.ac.uk.
  • Roobol MJ; Erasmus MC, Rotterdam, Netherlands.
  • Ribal MJ; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Abbott T; Astellas, Leiden, The Netherlands.
  • Agapow PM; Imperial College London, London, UK.
  • Araujo S; IQVIA, London, UK.
  • Asiimwe A; Bayer AG, Berlin, Germany.
  • Auffray C; Association EISBM, Vourles, France.
  • Balaur I; Association EISBM, Vourles, France.
  • Beyer K; Translational Oncology and Urology Research, King's College London, London, UK.
  • Bernini C; European Alliance for Personalised Medicine (EAPM), Brussels, Belgium.
  • Bjartell A; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Briganti A; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Butler-Ransohoff JE; Bayer AG, Berlin, Germany.
  • Campi R; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Cavelaars M; The Hyve, Utrecht, Netherlands.
  • De Meulder B; Association EISBM, Vourles, France.
  • Devecseri Z; Sanofi, Chilly-Mazarin, France.
  • Voss MD; Sanofi, Chilly-Mazarin, France.
  • Dimitropoulos K; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Evans-Axelsson S; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Franks B; Astellas, Leiden, The Netherlands.
  • Fullwood L; Pinsent Masons, Leeds, UK.
  • Horgan D; European Alliance for Personalised Medicine (EAPM), Brussels, Belgium.
  • Smith EJ; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Kiran A; Astellas, Leiden, The Netherlands.
  • Kivinummi K; Tampere University (TAU), Tampere, Finland.
  • Lambrecht M; SAS, Tervuren, Belgium.
  • Lancet D; Weizmann Institute, Rehovot, Israel.
  • Lindgren P; The Swedish Institute for Health Economics (IHE), Stockholm, Sweden.
  • MacLennan S; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • MacLennan S; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • Nogueira MM; Association EISBM, Vourles, France.
  • Moen F; The Swedish Institute for Health Economics (IHE), Stockholm, Sweden.
  • Moinat M; The Hyve, Utrecht, Netherlands.
  • Papineni K; Astellas, Leiden, The Netherlands.
  • Reich C; IQVIA, London, UK.
  • Reiche K; Fraunhofer IZI, Leipzig, Germany.
  • Rogiers S; SAS, Tervuren, Belgium.
  • Sartini C; Bayer AG, Berlin, Germany.
  • van Bochove K; The Hyve, Utrecht, Netherlands.
  • van Diggelen F; ttopstart, Utrecht, Netherlands.
  • Van Hemelrijck M; Translational Oncology and Urology Research, King's College London, London, UK.
  • Van Poppel H; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
  • Zong J; Bayer AG, Berlin, Germany.
  • N'Dow J; Guidelines Office, European Association of Urology, Arnhem, Netherlands.
Nat Rev Urol ; 17(6): 351-362, 2020 06.
Article em En | MEDLINE | ID: mdl-32461687
ABSTRACT
Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Pesquisa Biomédica / Big Data Limite: Humans / Male Idioma: En Revista: Nat Rev Urol Assunto da revista: UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Pesquisa Biomédica / Big Data Limite: Humans / Male Idioma: En Revista: Nat Rev Urol Assunto da revista: UROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido